OraSure Technologies Expands OraQuick® HIV Self-Test Age Range to Include Adolescents Aged 14 and Older

OraQuick® HIV Self-Test now approved for ages 14 and up, increasing access to HIV testing for adolescents.

Quiver AI Summary

OraSure Technologies has received approval to expand the age range for the OraQuick® HIV Self-Test to include adolescents aged 14 and older, previously limited to those 17 and older. This change aims to improve access to HIV testing for young people, who represent a significant percentage of new HIV diagnoses in the U.S., yet have low testing rates. OraSure's President and CEO, Carrie Eglinton Manner, emphasized the importance of increasing testing options as part of efforts to combat the HIV epidemic and ensure timely care for adolescents who test positive. The OraQuick® HIV Self-Test has been available since 2012 and includes educational materials to help users make informed decisions regarding their health.

Potential Positives

• Expansion of the OraQuick® HIV Self-Test to individuals aged 14 and older increases access to vital HIV testing for adolescents, addressing a significant public health need.
• The approval aligns with efforts to combat the HIV epidemic among young people, as 19 percent of new HIV diagnoses occur in those aged 13 to 24.
• Enhanced market potential by targeting a younger demographic that has previously had limited access to HIV testing, which may drive increased sales and brand awareness.
• The inclusion of robust educational materials and care linkage in the test packaging empowers users to make informed health decisions and reduces stigma related to HIV testing.

Potential Negatives

• Expanding the approved age range for the OraQuick® HIV Self-Test could highlight previous limitations and potentially raise concerns about the adequacy of testing options for younger populations prior to this change.
• The press release includes a lengthy forward-looking statement that outlines numerous risks and uncertainties, signaling potential challenges in future performance and market acceptance.
• The mention of significant HIV diagnosis rates among young people suggests that despite the new testing option, there is an ongoing public health issue that the company may be struggling to address effectively.

FAQ

What is the new age range for OraQuick® HIV Self-Test?

The OraQuick® HIV Self-Test is now approved for individuals aged 14 and older.

Why is the new approval for younger users important?

This approval increases access to HIV testing for adolescents, addressing a significant gap in awareness and testing.

How long has the OraQuick® HIV Self-Test been available?

The OraQuick® HIV Self-Test has been available to consumers in the U.S. since 2012.

What percentage of new HIV diagnoses are among young people?

19 percent of new HIV diagnoses in the U.S. are among individuals aged 13 to 24.

What support does the OraQuick® HIV Self-Test provide?

It includes educational materials and information for linking to care, helping individuals make informed decisions.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$OSUR Hedge Fund Activity

We have seen 82 institutional investors add shares of $OSUR stock to their portfolio, and 120 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• AMERICAN CAPITAL MANAGEMENT INC removed 939,467 shares (-78.9%) from their portfolio in Q3 2024
• GOLDMAN SACHS GROUP INC removed 568,792 shares (-52.5%) from their portfolio in Q3 2024
• ACADIAN ASSET MANAGEMENT LLC added 523,276 shares (+23.8%) to their portfolio in Q3 2024
• ACUITAS INVESTMENTS, LLC added 353,897 shares (+inf%) to their portfolio in Q3 2024
• ARCHON CAPITAL MANAGEMENT LLC added 337,743 shares (+inf%) to their portfolio in Q3 2024
• NEUBERGER BERMAN GROUP LLC added 315,492 shares (+8.7%) to their portfolio in Q3 2024
• MORGAN STANLEY removed 313,418 shares (-25.3%) from their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick

^®

HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick

^®

HIV Self-Test. Previously the test was approved for use in those 17 and older.

According to the most recent data available from the Centers for Disease Control & Prevention, it is estimated that 19 percent of new HIV diagnoses in the United States were among young people aged 13 to 24, and only 6 percent of high school students have ever been tested for HIV. Almost half of young people with HIV do not know that they have it.

“Increasing access to different testing options is critical to ending the HIV epidemic for all people, and early connection to care is essential for adolescents who test positive for HIV,” said Carrie Eglinton Manner, President and CEO of OraSure Technologies. “We are pleased that our OraQuick

^®

HIV Self-Test can now be used within this younger population who needs it, and we are proud of the work we have done to promote HIV testing, help people know their HIV status, and stop the stigma of infection. This approval will allow us to expand access to help those who need it.”

The OraQuick

^®

HIV Self-Test has been available direct to consumers in the U.S. since 2012. Since its launch, OraSure has been committed to providing consumers with access to critical information and connection to care. The packaging contains robust educational material and linkage to care information, giving individuals information that they can use to make informed decisions, regardless of the test result.

About OraSure Technologies, Inc.



OraSure Technologies, Inc. (“OraSure”) transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiaries, DNA Genotek Inc. and Sherlock Biosciences, Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit


www.orasure.com


.

Forward-Looking Statement



This press release contains certain forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to satisfy customer demand; ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to comply with applicable regulatory requirements; ability to meet increased demand for OraSure’s products; competition from new or better technology or lower cost products; changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention or other agencies; ability to obtain and maintain new or existing product distribution channels; impact of negative economic conditions; ability to maintain sustained profitability; changes in international, federal or state laws and regulations; equipment failures and ability to obtain needed raw materials and components. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and OraSure Technologies undertakes no duty to update these statements.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.